Upper limit maintain for PFaslodexㆍFulvetㆍGaster DㆍFamofang OD
[Newsmp] The health insurance coverage list now includes Onureg, the medication for treating acute myeloid leukemia by BMS Korea.
Pfizer Korea’s breast cancer treatment Ibrance has been listed as a tablet followed by capsules, and Sanofi’s type 2 inflammatory disease treatment Dupixent has been listed as a prefilled pen formulation at 200mg following 300mg.
The reimbursement ceiling for genetically modified recombinant leukemia therapies among current items has been lowered, and the reimbursement cap for Merck's PD-L1 immune checkpoint inhibitor, Bavencio, used in first-line maintenance therapy for urothelial carcinoma, has also been decreased.
The Ministry of Health and Welfare said on Wednesday it revised and issued a revision of the ‘Pharmaceutical benefit list and the table of the upper limit of benefits.’
According to the notice, Onureg has two options on the list, 200mg and 300mg. The upper limit was set at KRW 1,183,274 per party.
Ibrance now includes an additional tablet option, alongside its existing capsule formulation.
Just like the capsule form, tablets are now also available in three dosages: 75mg, 100mg, and 125mg, and the reimbursement ceiling for all three dosages has been set at KRW 113,292, the same as the capsule form.
Dupixent was added with an additional 200mg of prefilled pen, and the upper limit was listed at KRW 607,976, the same as the previously registered prefilled Inj. 200mg.
The reimbursement cap for genetically modified recombinant hemophilia treatments, such as Takeda Korea's Advate and Adynovate, Pfizer Korea's Xyntha Solofuse, and Sanofi's Eloctate, has been uniformly reduced.
Advate has been lowered by 4.9~5.6% from KRW 445~448 per IU to KRW 423 for all four dosages, Adynovate by 5.5% from KRW 675 per IU to KRW 638 for all five dosages, Xyntha Solofuse by 0.2% from KRW 511 per IU to KRW 510 for all five dosages, and Eloctate by 0.1% from KRW 675 per IU to KRW 674 for all four dosages.
Merck's immune checkpoint inhibitor, Bavencio, has seen a price reduction of 30.4%, from KRW 1,226,243 per 10ml vial to KRW 854,864, while Amgen's Prolia Prefilled Syringe for osteoporosis treatment has been decreased from KRW 168,800 per tube to KRW 162,600, a reduction of 3.7%
Moreover, Livalozet, JW Pharmaceutical's treatment for dyslipidemia, has been reduced by 9.1% for the 2/10 mg dosage from KRW 1,438 to KRW 1,307 and by the same percentage for the 4/10 mg dosage from KRW 1,746 to KRW 1,587, while Baraclude, BMS Korea's hepatitis B treatment, has been decreased by 0.8% for the 0.5 mg dosage from KRW 3,030 to KRW 3,006 and by the same percentage for the 1.0 mg dosage from KRW 3,430 to KRW 3,403.
The effective date for newly added items and the reimbursement cap reduction for existing items on the benefit list will be on the 1st of next month (August).
Five items, including Gaster D 20mg (Dong-A ST) and Famofang OD 10mg and 20mg (Pharmbio Korea) for peptic ulcers, as well as Faslodex (AstraZeneca Korea) and Fulvet (Boryung Pharmaceutical) for breast cancer treatment, which were initially scheduled for a reimbursement cap reduction on the 1st of next month, will maintain their current caps, and the planned reduction will now take effect on August 1, 2025.